Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Holdings Raised by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 15.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,213,029 shares of the company's stock after acquiring an additional 160,490 shares during the period. Dimensional Fund Advisors LP owned about 2.13% of Harmony Biosciences worth $41,739,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Harmony Biosciences by 92.6% during the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after acquiring an additional 436 shares during the period. Mendota Financial Group LLC increased its stake in Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock valued at $33,000 after purchasing an additional 965 shares during the last quarter. KBC Group NV raised its stake in Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after acquiring an additional 819 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after acquiring an additional 519 shares during the last quarter. Finally, Summit Investment Advisors Inc. boosted its stake in Harmony Biosciences by 34.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company's stock valued at $137,000 after acquiring an additional 1,029 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company's stock.

Wall Street Analysts Forecast Growth

HRMY has been the subject of a number of recent research reports. UBS Group decreased their price objective on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday, April 28th. HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Needham & Company LLC restated a "buy" rating and set a $49.00 price objective on shares of Harmony Biosciences in a research report on Tuesday. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective for the company. Finally, Mizuho raised their price objective on Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research note on Tuesday, March 18th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $52.33.

Harmony Biosciences Trading Up 0.4 %

Shares of Harmony Biosciences stock traded up $0.14 during trading hours on Friday, reaching $34.23. The stock had a trading volume of 120,325 shares, compared to its average volume of 583,362. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of 16.22, a P/E/G ratio of 0.47 and a beta of 0.82. Harmony Biosciences Holdings, Inc. has a 1 year low of $26.47 and a 1 year high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The firm has a 50 day simple moving average of $31.35 and a two-hundred day simple moving average of $34.01.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $184.73 million for the quarter, compared to analysts' expectations of $184.26 million. During the same period in the previous year, the company posted $0.67 earnings per share. Harmony Biosciences's revenue was up 19.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.